In a report released today, Kyle Rose from Canaccord Genuity maintained a Hold rating on Zimmer Biomet Holdings (NYSE: ZBH), with a price target of $125. The company’s shares closed on Friday at $126.20, close to its 52-week high of $129.34.
According to TipRanks.com, Rose is a 4-star analyst with an average return of 10.9% and a 55.7% success rate. Rose covers the Healthcare sector, focusing on stocks such as Smith & Nephew Snats, Stryker Corporation, and Rewalk Robotics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Zimmer Biomet Holdings with a $134 average price target, which is a 6.2% upside from current levels. In a report released yesterday, Piper Jaffray also reiterated a Hold rating on the stock with a $120 price target.
.
See today’s analyst top recommended stocks >>
Zimmer Biomet Holdings’ market cap is currently $25.66B and has a P/E ratio of 15.04. The company has a Price to Book ratio of 2.14.
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is negative on the stock. Most recently, in May 2018, Katarzyna Mazur-Hofsaess, the Pres., Eur., M. East & Afr. of ZBH sold 8,765 shares for a total of $995,792.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zimmer Biomet Holdings, Inc. designs, manufactures and markets orthopaedic reconstructive products, sports medicine, extremities and trauma products; craniomaxillofacial and thoracic products; dental implants; and related surgical products. The company operates through three geographical segments: America, Europe and Asia Pacific.
